Protara’s cell therapy shows treatment durability in mid-stage NMIBC study
Protara Therapeutics’ solid tumour-focused cell therapy, TARA-002, has demonstrated its potential to elicit a durable response in patients with non-muscle…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
Nonprofits join forces to debut marketplace for shelved CGTs
The American Society of Gene & Cell Therapy (ASCGT) and Orphan Therapeutics Accelerator (OTXL) have teamed up to launch an…
-
Biogen forges on with Alzheimer’s therapy development despite Phase II miss
Biogen is firing up a registrational programme for its tau-focused Alzheimer’s disease therapy, diranersen, despite the drug missing its primary…
-
Three PsA trials to watch in 2026
With the European Alliance of Associations for Rheumatology’s (EULAR) 2026 meeting less than a month away, physicians, researchers and other…
-
Shionogi weighs future of FXS drug after double Phase III miss
Shionogi is mulling over the fate of its fragile X syndrome (FXS) therapy, zatolmilast, after the drug failed to meet…
-
Novo Nordisk’s high-dose Wegovy touts near 28% weight loss in early responders
Novo Nordisk has shared new data that suggests a higher dose version of its blockbuster weight loss drug, Wegovy (semaglutide),…
-
BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial
BridgeBio has revealed new pivotal trial data for Attruby (acoramidis) along with results from an indirect comparison to Pfizer’s Vyndamax…
-
WhiteSwell’s heart failure device promising but patient death rattles results
WhiteSwell has debuted promising early data from a feasibility study on its eLym system in acute decompensated heart failure (ADHF),…
-
FDA locks down post-approval pregnancy safety data framework
The US Food and Drug Administration (FDA) has debuted its final industry guidance on collecting post-marketing safety data for both…
-
Entrada’s stock drops as DMD drug’s efficacy falls short
Entrada Therapeutics’ stock value has dropped by more than 57% after the efficacy of its Duchenne muscular dystrophy (DMD) therapy,…